Electroporation of CRISPR-Cas9 into Malignant B Cells for Loss-of-Function Studies of Target Gene Via Knockout

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Malignant B cells are difficult to transfect using conventional methods.
• CRISPR-Cas9 gene editing offers powerful tools for studying cancer biology and treatment.
• Developing efficient gene editing models for malignant B cells is crucial for research.

Purpose of the Study:

• To establish an efficient method for CRISPR-Cas9 delivery into malignant B cells.
• To generate a ROR1-gene knockout malignant B cell model (JEKO-1) for research.
• To optimize transfection conditions for CRISPR-Cas9 in difficult-to-transfect cell lines.

Main Methods:

• Utilized CRISPR-Cas9 technology for targeted gene editing.
• Employed Nucleofector™ Technology-based electroporation for cell transfection.
• Optimized transfection parameters specifically for the JEKO-1 malignant B cell line.
• Validated ROR1 gene knockout in the engineered JEKO-1 cells.

Main Results:

• Successfully achieved ROR1 gene knockout in JEKO-1 cells using CRISPR-Cas9.
• Demonstrated the efficacy of Nucleofector™ Technology for transfecting malignant B cells.
• Established a reliable method for generating genetically modified malignant B cell models.
• The optimized protocol provides a robust approach for CRISPR-Cas9 applications in challenging cell types.

Conclusions:

• Nucleofector™ Technology-based electroporation enables efficient CRISPR-Cas9 gene editing in malignant B cells.
• The generated JEKO-1 ROR1-knockout model serves as a valuable tool for studying B cell malignancies.
• This optimized transfection strategy facilitates the advancement of cancer research and therapeutic development.